OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: John Gerdes

1 Projects | 1 Researchers | $308,869 Invested

2019

RIO Pharmaceuticals, Inc.

John Gerdes, PhD

Human PET Imaging Evaluations of the Astroglial L-Glutamate EAAT2 Tracer for Alzheimer’s Disease and Related Dementias

  • Funding Amount: $308,869
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed